KAMALVEER GREWAL: Open Payments
NPI 1902301203 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$671 in 6 payments from 5 companies in 2025. Trend: 2023 $0 · 2024 $147 · 2025 $671
Food & beverage: $671
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $227 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| ABBVIE INC. | 1 | $115 |
| Supernus Pharmaceuticals, Inc. | 1 | $103 |
| Neurocrine BioSciences, Inc. | 1 | $101 |
Products named: AUSTEDO XR, Auvelity, VRAYLAR, Qelbree, INGREZZA.
Industry payments across NY — which companies pay providers there.
